Education
About Us
Working with TipRanks
Follow Us
FYX - ETF AI Analysis
Top Page
First Trust Small Cap Core AlphaDEX Fund (FYX)
Rating:64Neutral
Price Target:
$111.00
Positive Factors
Strong Top Holdings
Several of the ETF's top holdings, such as Praxis Precision Medicines and Microvast Holdings, have delivered strong year-to-date performance, boosting overall returns.
Sector Diversification
The ETF is spread across multiple sectors, including Industrials, Financials, and Health Care, reducing reliance on any single industry.
Steady Performance
The ETF has shown consistent positive returns over the year-to-date, three-month, and one-month periods, indicating solid momentum.
Negative Factors
High Geographic Concentration
The ETF is heavily focused on U.S. companies, with over 99% exposure, limiting diversification across global markets.
Underperforming Holding
Liberty Oilfield Services has posted negative year-to-date performance, which could weigh on the fund's overall returns.
Moderate Expense Ratio
The ETF's expense ratio of 0.6% is higher than some low-cost alternatives, potentially reducing net returns for investors.
FYX vs. SPDR S&P 500 ETF (SPY)
AUM850.56M
RegionNorth America
Expense Ratio0.60%
Beta1.02
IssuerFirst Trust
Inception DateMay 08, 2007
Dividend Yield0.91%
Asset ClassEquity
Index TrackedNasdaq AlphaDEX Small Cap Core Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume13,995
30 Day Avg. Volume14,347
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
131.10Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering526
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FYX Summary
The First Trust Small Cap Core AlphaDEX Fund (FYX) is an ETF that focuses on small-cap companies in the U.S., following the Nasdaq AlphaDEX Small Cap Core Index. It includes a mix of industries like healthcare, technology, and financials, with holdings such as Praxis Precision Medicines and Microvast Holdings. Investors might consider FYX for its potential growth opportunities, as small-cap companies often have room to expand and innovate. However, new investors should be aware that small-cap stocks can be more volatile than larger companies, meaning their prices may rise and fall more dramatically.
How much will it cost me?The expense ratio for FYX is 0.6%, which means you’ll pay $6 per year for every $1,000 invested. This is slightly higher than average because FYX uses an actively managed AlphaDEX methodology to select stocks rather than passively tracking an index.
What would affect this ETF?FYX, focusing on U.S. small-cap stocks, could benefit from economic growth and innovation in sectors like technology and healthcare, which are key components of its holdings. However, it may face challenges from rising interest rates or economic slowdowns, which can disproportionately impact smaller companies and sectors like consumer cyclical and financials. Regulatory changes or shifts in market sentiment could also affect the performance of its top holdings in industries such as energy and pharmaceuticals.
FYX Top 10 Holdings
The FYX ETF is a small-cap fund with a diverse sector mix, but its performance is being shaped by a few standout names. Cidara Therapeutics is rising fast, driven by strong technical momentum and promising developments in its pipeline, making it a key driver for the fund. Meanwhile, Liberty Oilfield Services is lagging, weighed down by declining profitability despite some optimism around its strategic expansions. The fund leans heavily into health care and industrials, showcasing its focus on innovation and growth, while its U.S.-centric exposure keeps it tied to domestic market dynamics.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines | 0.62% | $5.47M | $4.25B | 127.92% | 56 Neutral | |
| Globalstar | 0.51% | $4.45M | $7.20B | 111.55% | 58 Neutral | |
| Avadel Pharmaceuticals | 0.49% | $4.30M | $2.25B | 97.51% | 57 Neutral | |
| Travere Therapeutics | 0.47% | $4.13M | $3.10B | 90.08% | 55 Neutral | |
| Alphatec Holdings | 0.45% | $3.98M | $3.02B | 101.89% | 58 Neutral | |
| Cidara Therapeutics | 0.45% | $3.91M | $6.90B | 975.24% | 57 Neutral | |
| NewAmsterdam Pharma Company | 0.44% | $3.83M | $4.34B | 89.46% | 58 Neutral | |
| Liberty Oilfield Services | 0.43% | $3.79M | $2.66B | -13.64% | 68 Neutral | |
| Liquidia Technologies | 0.42% | $3.65M | $2.53B | 173.33% | 57 Neutral | |
| GRAIL Inc | 0.41% | $3.60M | $3.65B | 466.80% | 67 Neutral |
FYX Technical Analysis
Positive
―
Price Trends
108.95
Negative
105.73
Positive
98.89
Positive
Market Momentum
-1.00
Positive
46.90
Neutral
20.36
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FYX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 108.34, equal to the 50-day MA of 108.95, and equal to the 200-day MA of 98.89, indicating a neutral trend. The MACD of -1.00 indicates Positive momentum. The RSI at 46.90 is Neutral, neither overbought nor oversold. The STOCH value of 20.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FYX.
FYX Peer Comparison
Comparison Results
Performance Comparison
FYX
First Trust Small Cap Core AlphaDEX Fund
107.00
-2.53
-2.31%
OUSM
OShares U.S. Small-Cap Quality Dividend ETF
―
―
―
DWAS
Invesco DWA SmallCap Momentum ETF
―
―
―
GSSC
Goldman Sachs Activebeta U.S. Small Cap Equity ETF
―
―
―
SMDV
ProShares Russell 2000 Dividend Growers ETF
―
―
―
JHSC
John Hancock Multifactor Small Cap ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents